What are the indications, recommended oral dosing, administration guidelines, treatment duration, side effect management, alternative formulations, intravenous options, and contraindications for iron supplementation in patients with iron‑deficiency anemia?

Iron Supplementation in Iron‑Deficiency Anemia

Start oral ferrous sulfate 200 mg (≈65 mg elemental iron) once daily immediately upon diagnosis, add vitamin C 500 mg with each dose, and continue for 3 months after hemoglobin normalizes—switching to intravenous iron only when oral therapy fails after 4 weeks, the patient cannot tolerate at least two different oral formulations, or specific conditions (active IBD with Hb <10 g/dL, post‑bariatric surgery, severe anemia with hemodynamic instability) are present. 1, 2

Indications for Iron Supplementation

• Iron supplementation is indicated when serum ferritin is <30 ng/mL in patients without inflammation, or <100 ng/mL with transferrin saturation <20% in patients with inflammatory conditions. 1, 2
• Hemoglobin <12 g/dL in women or <13 g/dL in men defines anemia requiring treatment when iron deficiency is confirmed. 2, 3
• Non‑anemic iron deficiency (ferritin <30 ng/mL with normal hemoglobin) warrants treatment in symptomatic patients with fatigue, restless legs syndrome, or pica. 3, 4

Recommended Oral Dosing

• Ferrous sulfate 200 mg once daily (containing ≈65 mg elemental iron) is the preferred first‑line regimen because it provides superior cost‑effectiveness with efficacy comparable to all other oral formulations. 1, 2, 5
• Once‑daily dosing is superior to multiple daily doses because hepcidin remains elevated for approximately 48 hours after iron ingestion, blocking subsequent absorption and increasing gastrointestinal side effects without improving hemoglobin response. 1, 2, 5
• Alternate‑day dosing (every other day) may improve tolerability with similar or better efficacy by allowing hepcidin levels to decrease between doses. 2, 5
• Alternative formulations—ferrous fumarate (≈106 mg elemental iron per 325 mg tablet) or ferrous gluconate (≈38 mg elemental iron per 325 mg tablet)—are equally effective if ferrous sulfate is not tolerated. 1, 2, 5

Administration Guidelines

• Take oral iron on an empty stomach for maximal absorption; if gastrointestinal intolerance occurs, it may be taken with food. 2, 5
• Co‑administer vitamin C (ascorbic acid) 500 mg with each iron dose to markedly enhance absorption, especially when transferrin saturation is severely low. 1, 2, 5
• Avoid tea and coffee for at least 1 hour after the iron dose because they strongly inhibit absorption. 2
• Do not take iron within 2 hours of antacids, calcium supplements, or proton‑pump inhibitors, as these reduce absorption. 2

Treatment Duration

• Check hemoglobin at 4 weeks; an increase of approximately 2 g/dL is expected with adequate therapy. 1, 2, 5
• Continue oral iron for 3 months after hemoglobin normalizes to fully replenish iron stores; total treatment duration is typically 6–7 months. 1, 2, 5
• Monitor hemoglobin and red‑cell indices every 3 months during the first year, then annually thereafter. 1, 2, 5

Side Effect Management

• Gastrointestinal side effects (nausea, constipation, abdominal discomfort) occur in 20–40% of patients taking oral iron. 1, 2
• If side effects occur with ferrous sulfate, switch to ferrous fumarate or ferrous gluconate, which have comparable efficacy. 1, 2, 5
• Reduce dosing frequency to every other day if daily dosing is not tolerated; this maintains similar efficacy while improving tolerance. 2, 5
• Taking iron with food reduces side effects but also decreases absorption by approximately 40–50%; this trade‑off is acceptable if it improves adherence. 2, 5

Alternative Oral Formulations

• Ferric maltol (30 mg twice daily) is an alternative for patients with inactive IBD who have failed traditional iron salts; it normalized hemoglobin in 63–66% of cases after 12 weeks in clinical trials. 1
• Ferric maltol has comparable gastrointestinal side effects to placebo but is considerably more expensive than traditional iron salts. 1
• Polysaccharide‑iron complex and heme‑iron polypeptide are marketed as better‑tolerated alternatives, but no high‑quality evidence supports superior efficacy or tolerability compared to ferrous sulfate. 2

Intravenous Iron Options

Absolute Indications for IV Iron (First‑Line)

• Active inflammatory bowel disease with hemoglobin <10 g/dL: IV iron is first‑line because inflammation‑driven hepcidin markedly impairs oral absorption and oral iron may worsen intestinal inflammation. 1, 2, 5
• Post‑bariatric surgery patients: IV iron is preferred due to disrupted duodenal absorption mechanisms. 2, 5
• Severe symptomatic anemia with hemodynamic instability: Use restrictive packed red‑cell transfusion (target Hb 7–9 g/dL) followed by IV iron. 2

Relative Indications for IV Iron (After Oral Failure)

• Documented intolerance to at least two different oral iron formulations (e.g., ferrous sulfate and ferrous fumarate or gluconate). 1, 2, 5
• Ferritin levels fail to improve after 4 weeks of compliant oral therapy. 1, 2, 5
• Hemoglobin fails to increase by ≥1 g/dL after 4 weeks of adequate oral iron. 2
• Celiac disease with inadequate response to oral iron despite strict gluten‑free diet adherence. 2, 5
• Chronic heart failure with iron deficiency (ferritin <100 ng/mL or 100–300 ng/mL with transferrin saturation <20%), where IV iron improves symptoms and quality of life. 2, 5
• Ongoing gastrointestinal blood loss that exceeds the replacement capacity of oral iron. 2, 5

Preferred IV Iron Formulations

• Choose IV iron products that can replace the total iron deficit in 1–2 infusions to minimize infusion‑related risk and improve convenience. 1, 2, 5
• Ferric carboxymaltose: 750–1000 mg administered over 15 minutes; two doses given ≥7 days apart provide a cumulative 1500 mg. 1, 2, 5
• Ferric derisomaltose: 1000 mg can be given as a single infusion. 2, 5
• Iron dextran should be avoided as first‑line therapy because it carries a higher anaphylaxis risk (≈0.6–0.7%); most reactions are complement‑activation pseudo‑allergies that respond to slowing the infusion rate. 1, 2, 5
• All IV iron administrations must occur in a setting equipped with resuscitation facilities. 1, 2, 5

Expected Response to IV Iron

• IV iron typically raises hemoglobin by approximately 2 g/dL within 3–4 weeks; meaningful improvement can be observed as early as 7–12 days in severe cases. 2, 5
• In patients with active IBD and hemoglobin <10 g/dL, IV iron yields a higher likelihood of achieving a ≥2.0 g/dL hemoglobin increase (odds ratio 1.57) compared to oral iron. 2, 5

Contraindications

Absolute Contraindications to Oral Iron

• Active inflammatory bowel disease with hemoglobin <10 g/dL—use IV iron instead because oral iron is poorly absorbed and may exacerbate intestinal inflammation. 1, 2, 5
• Colonoscopy scheduled within the next few days—oral iron can impair endoscopic visualization. 1, 2

Relative Contraindications to Oral Iron

• Severe symptomatic anemia with circulatory compromise (tachycardia, hypotension, altered mental status, acute heart failure)—use restrictive transfusion followed by IV iron. 2
• Post‑bariatric surgery with disrupted duodenal anatomy—IV iron is preferred. 2, 5
• Celiac disease with ongoing gluten exposure—ensure strict gluten‑free diet before starting oral iron. 2, 5

Contraindications to IV Iron

• Known hypersensitivity to the specific IV iron formulation. 2
• Active bacterial infection (relative contraindication)—defer IV iron until infection is controlled. 2
• First trimester of pregnancy (relative contraindication)—oral iron is preferred; IV iron is safe during second and third trimesters. 2, 3

Special Population Considerations

Inflammatory Bowel Disease

• In active IBD with hemoglobin <10 g/dL, IV iron is first‑line therapy; oral iron is poorly absorbed and may worsen inflammation. 1, 2, 5
• For mild anemia (hemoglobin >10 g/dL) with clinically inactive disease, oral iron may be used if the disease is truly quiescent. 2, 5
• Elemental iron doses should not exceed 100 mg per day in IBD patients, as higher oral doses may trigger intestinal inflammation. 2
• After successful IV iron therapy, re‑initiate iron supplementation when ferritin falls below 100 ng/mL or hemoglobin drops below 12 g/dL in women or 13 g/dL in men. 2

Pregnancy

• Start oral low‑dose iron 30 mg/day at the first prenatal visit for prevention. 2, 5
• Treat anemia with 60–120 mg/day elemental iron. 2, 5
• Refer pregnant women with hemoglobin <9.0 g/dL for further medical evaluation. 2
• IV iron is safe and effective during the second and third trimesters when oral iron fails to correct anemia. 2, 3

Chronic Kidney Disease (Non‑Dialysis)

• Start iron supplementation when hemoglobin <11 g/dL and ferritin <100 ng/mL or transferrin saturation <20%. 2
• Maintain ferritin ≥100 ng/mL and transferrin saturation ≥20% during therapy. 2
• Either oral or IV iron may be used in non‑dialysis CKD stages 3–5; IV iron is preferred for hemodialysis patients. 2

Chronic Heart Failure

• Screen for iron deficiency with ferritin and transferrin saturation. 2
• IV iron improves symptoms and quality of life in heart failure patients with functional iron deficiency (ferritin <100 ng/mL or 100–300 ng/mL with transferrin saturation <20%). 2, 5

Post‑Bariatric Surgery

• IV iron is preferred due to anatomic disruption of duodenal iron absorption. 2, 5
• A single dose of IV iron is more effective and better tolerated than oral ferrous fumarate or ferrous gluconate. 2

Celiac Disease

• Ensure strict adherence to a gluten‑free diet to improve iron absorption. 2, 5
• Consider oral iron supplementation based on severity of iron deficiency and patient tolerance. 2
• Progress to IV iron if iron stores do not improve despite dietary compliance. 2, 5

Common Pitfalls to Avoid

• Do not prescribe multiple daily doses of oral iron—this increases side effects without improving efficacy due to hepcidin‑mediated absorption blockade. 1, 2, 5
• Do not discontinue iron therapy when hemoglobin normalizes—continue for an additional 3 months to restore iron stores. 1, 2, 5
• Do not persist with oral iron beyond 4 weeks without a hemoglobin rise—reassess for malabsorption, ongoing loss, or need for IV iron. 2, 5
• Do not overlook vitamin C supplementation when oral iron response is suboptimal—it markedly enhances absorption. 1, 2, 5
• Do not fail to identify and treat the underlying cause of iron deficiency while providing supplementation—all adult men and post‑menopausal women require bidirectional endoscopy to exclude gastrointestinal malignancy. 1, 2
• Do not use oral iron in active IBD patients with hemoglobin <10 g/dL—IV iron is the appropriate first‑line option. 1, 2, 5
• Do not transfuse routinely at low hemoglobin levels in hemodynamically stable patients—IV iron is safer and equally effective. 2
• Do not check ferritin levels immediately after IV iron infusion—wait 8–10 weeks, as levels are falsely elevated. 5

Failure‑to‑Respond Algorithm

If hemoglobin fails to rise by ≥1 g/dL after 4 weeks of adequate oral iron:

1. Verify adherence to oral iron therapy. 2
2. Evaluate for ongoing blood loss (repeat endoscopy or video‑capsule endoscopy). 2
3. Consider malabsorption syndromes (celiac disease, IBD, post‑bariatric surgery). 2
4. Check for concurrent vitamin B12 or folate deficiency. 2
5. Assess for systemic disease, bone‑marrow pathology, or hemolysis. 2
6. Switch to intravenous iron if oral therapy failure is confirmed. 2

If anemia persists after 6 months of appropriate iron therapy, reassess for ongoing blood loss, evaluate for malabsorption syndromes, and consider further gastrointestinal investigation. 1, 2